163 related articles for article (PubMed ID: 31409190)
1. Outcomes Associated With the Adjunctive Use of Dipeptidyl Peptidase-4 Inhibitors With Insulin Versus Other Antihyperglycemic Medications in Patients With Prediabetes or Diabetes After Cardiac Surgery.
Clark L; Weeda E; Griffin ML; Jones LA; Haney J
J Pharm Pract; 2021 Apr; 34(2):259-264. PubMed ID: 31409190
[TBL] [Abstract][Full Text] [Related]
2. Safety And Efficacy Of Dpp-4 Inhibitors For The Management Of Hospitalized General Medicine And Surgery Patients with Type 2 Diabetes.
Lorenzo-González C; Atienza-Sánchez E; Reyes-Umpierrez D; Vellanki P; Davis GM; Pasquel FJ; Cardona S; Fayfman M; Peng L; Umpierrez GE
Endocr Pract; 2020 Jul; 26(7):722-728. PubMed ID: 33471640
[TBL] [Abstract][Full Text] [Related]
3. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in the Inpatient Setting.
Petite SE; Hill MC
J Pharm Pract; 2022 Apr; 35(2):229-234. PubMed ID: 33094657
[TBL] [Abstract][Full Text] [Related]
5. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
Xu L; Zheng XQ; Liao XX
Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
[TBL] [Abstract][Full Text] [Related]
8. Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.
Yang W; Cai X; Gao X; Chen Y; Chen L; Ji L
J Diabetes Investig; 2018 Jul; 9(4):813-821. PubMed ID: 29047219
[TBL] [Abstract][Full Text] [Related]
9. Effect of dipeptidyl peptidase-4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus.
Choi Y; Ko SH; Chang K; Yoo KD; Ihm SH
J Diabetes; 2023 Nov; 15(11):944-954. PubMed ID: 37528628
[TBL] [Abstract][Full Text] [Related]
10. Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.
Li PF; Chung CH; Liu JS; Lu CH; Su SC; Kuo FC; Ho LJ; Chen KC; Su YT; Chu NF; Lee CH; Hsieh CH; Hung YJ; Lin FH; Chien WC; Liang YJ
Ther Adv Respir Dis; 2022; 16():17534666221135320. PubMed ID: 36448591
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.
Bouzas C; Pastor R; Garcia S; Monserrat-Mesquida M; Martínez-González MÁ; Salas-Salvadó J; Corella D; Goday A; Martínez JA; Alonso-Gómez ÁM; Fernández-Barceló O; Vioque J; Romaguera D; Lopez-Miranda J; Estruch R; Tinahones FJ; Lapetra J; Serra-Majem L; Riquelme-Gallego B; Martín-Sánchez V; Pintó X; Delgado-Rodriguez M; Matía P; Vidal J; Cardenas-Salas JJ; Daimiel L; Ros E; Toledo E; Manzanares JM; Gonzalez-Monge I; Muñoz MÁ; Martinez-Urbistondo D; Tojal-Sierra L; Muñoz-Bravo C; Miralles-Gisbert S; Martin M; García-Ríos A; Castro-Barquero S; Fernández-García JC; Santos-Lozano JM; Basterra-Gortari FJ; Gutiérrez-Carrasquilla L; Guillem-Saiz P; Satorres A; Abete I; Sorto-Sanchez C; Díez-Espino J; Babio N; Fitó M; Tur JA
Biomed Pharmacother; 2023 May; 161():114561. PubMed ID: 36934556
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer.
Saito A; Kitayama J; Horie H; Koinuma K; Kawashima R; Ohzawa H; Yamaguchi H; Kawahira H; Mimura T; Lefor AK; Sata N
Cancer Res Commun; 2021 Nov; 1(2):106-114. PubMed ID: 36860286
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
Sugiyama S; Yamamoto T; Aoyama Y
J Dermatol; 2022 Jul; 49(7):697-702. PubMed ID: 35478414
[TBL] [Abstract][Full Text] [Related]
15. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan.
Chang CH; Lu CH; Chung CH; Su SC; Kuo FC; Liu JS; Li PF; Huang CL; Chen KC; Ho LJ; Kuo CC; Chang CY; Lin MS; Liu YC; Chu NF; Lee CH; Hung YJ; Hsieh PS; Lin FH; Hsieh CH; Chien WC
J Chin Med Assoc; 2022 Jul; 85(7):747-753. PubMed ID: 35648138
[TBL] [Abstract][Full Text] [Related]
17. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
[TBL] [Abstract][Full Text] [Related]
18. Effect of dipeptidyl peptidase-4 inhibitors on glycated hemoglobin levels relies on dietary sodium intake.
Okada S; Okada K; Okada J; Kikkawa K; Yamada E; Saito T; Andou T; Ohshima K
Diabetes Metab Syndr; 2023 Jul; 17(7):102806. PubMed ID: 37343509
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in Hospitalized Patients With Diabetes.
Petite SE; Hill MC
Ann Pharmacother; 2021 Nov; 55(11):1326-1332. PubMed ID: 33615832
[TBL] [Abstract][Full Text] [Related]
20. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Seong JM; Kim JJ; Kim HJ; Sohn HS
Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
